Nintedanib+Letrozole in Postmenopausal Women With Breast Cancer: Clinical Trial Safety and Pharmacodynamics
|The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.|
|ClinicalTrials.gov Identifier: NCT02619162|
Recruitment Status : Completed
First Posted : December 2, 2015
Last Update Posted : July 23, 2019
- Study Details
- Tabular View
- Results Submitted
- How to Read a Study Record
|Condition or disease||Intervention/treatment||Phase|
|Breast Cancer||Drug: Nintedanib Drug: Letrozole||Phase 1|
Phase 0 / I:
At level 1 it includes three patients. If any patient suffers dose limiting toxicity (DLT), it proceeds to the increase in dose to the next level. If 2/3 patients experience DLT, he will close the increased dose and extended / investigate the previous dose level with 3 additional patients.
If the level 2, but less than 1/3 the minimum of 6 patients experience TLD is reached, the phase I be suspended because not expected another rise above Level 2.
- Level 1: Nintedanib 150 mg twice daily + oral letrozole 2.5 mg / day orally, in a cycle of 28 days.
- Level 2: Nintedanib 200 mg twice daily via oral + letrozole 2.5 mg / day orally, in a cycle of 28 days.
- At least the first cycle will be administered during Phase I. A total of six four-week cycles were administered at the discretion of the investigator.
|Study Type :||Interventional (Clinical Trial)|
|Actual Enrollment :||25 participants|
|Intervention Model:||Single Group Assignment|
|Masking:||None (Open Label)|
|Official Title:||Nintedanib Plus Letrozole in Postmenopausal Women With Breast Cancer: Clinical Trial Phase 0/1 Safety and Pharmacodynamics|
|Actual Study Start Date :||July 2015|
|Actual Primary Completion Date :||November 2017|
|Actual Study Completion Date :||June 2018|
Tablets of 100 mg. or 150 mg.
Other Name: BIFF 1120
Tablet of 2.5 mg.
- Dose limiting toxicity [ Time Frame: 1-6 months ]Classified according to the version 4.03 of CTCAE criteria NCI1
- Evaluating FGFR1 modulation and inhibition levels of 17-B Estradiol [ Time Frame: 1-6 months ]Assess the pharmacodynamic modulation of FGFR1 and inhibition levels of 17-B: determine plasma levels of FGF 23 ang 17- B estradiol (pg/mL)
- Pharmacokinetic interactions [ Time Frame: 29 days ]Determine the pharmacokinetic interactions nintedanib combined with letrozole: determine plasma levels of Nintedanib and Letrozole at day 0, day 15 and day 29 (Cmax)
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.
|Ages Eligible for Study:||18 Years and older (Adult, Older Adult)|
|Sexes Eligible for Study:||Female|
|Accepts Healthy Volunteers:||No|
- Form signed informed consent.
- Women ≥ 18 years.
- Confirmed diagnosis of invasive non-metastatic breast cancer positive for hormone receptors. The inclusion of patients with ductal or lobular histology allowed.
- Size greater than 1 cm tumor and any N or N ≥ 1 and any T, including inflammatory breast cancer.
- Absence of metastatic involvement.
- Postmenopausal state. Postmenopausal status is defined as more than 24 months after the last menstrual period, or previous known ovariectomy, or chemical, determined by FSH, LH and estradiol 17-B according to the local laboratory values over 12 months without menstruation.
- ECOG performance status of 0 or 1
- At least one month after the end of radiotherapy and / or chemotherapy.
- At least 6 weeks since major surgery.
- Patients currently treated with letrozole less than 6 months.
- Primary surgery for breast cancer already done. The elderly women with advanced local or regional tumors in which hormone treatment is administered as monotherapy, regardless of the intent of the surgery are not candidates.
- LVEF> 50%
Renal function, liver and adequate hematologic, defined by the following analytical results within 14 days prior to randomization or registration:
- Absolute granulocyte count> 1.5 x 109 / L
- Absolute platelet count> 100 x 109 / L
- Hemoglobin> 10 g / dl
- Serum creatinine ≤ 1.5 x ULN or calculated creatinine clearance> 50 ml / min
- Serum bilirubin <1.25 ULN
- AST / ALT ≤ 1.5 times the LS
- Toxicities associated with chemotherapy recovery lesser extent 2 not tolerable.
- Life expectancy> 6 months.
- HER2 overexpression defined as positive by immunohistochemistry HER-2-positive 2+ 3+ or FISH / CISH.
- Absence of tumor tissue file.
- T1 N0 stage patients are excluded.
- Malignancy concomitant active, or diagnosis of another malignancy within the last five years, apart from non-melanoma or ductal / tubular breast carcinoma skin cancer (not received hormone treatment) or in situ cervical cancer, carcinoma colon in situ treated properly, as well as any diagnosis of tumor less than five years before the inclusion unsigned progression today.
- Women of childbearing potential.
- Pretreatment nintedanib. Use of other investigational drugs during the administration of adjuvant or neoadjuvant treatment is not an exclusion criterion as long as toxicity recovers.
- Medical Condition concomitant serious, like eg myocardial infarction within 6 uncontrolled prior to inclusion in the study months, congestive heart failure, unstable angina, cardiomyopathy active, unstable ventricular arrhythmia, hypertension (according to the criteria of the NYHA) , psychotic disorders uncontrolled severe active infections, active peptic ulcer disease, psychiatric disease, HIV infection, active hepatitis, COPD or any other medical condition that might be aggravated by treatment or limits compliance.
- Inability to make oral, or history of malabsorption syndrome medication.
- Failure to comply with the study and follow-up procedures.
- Anticoagulant therapy (except low-dose heparin or heparin washing as needed to maintain a permanent intravenous device) or antiplatelet therapy (except low-dose therapy with aspirin, less than 325 mg daily).
- History of thromboembolic or hemorrhagic episodes that are clinically relevant in the past 6 months or hereditary predisposition to bleeding or thrombosis.
- Contraindication to hormonal blockade or absence of hormone-blocking prescription from your doctor for any reason. Metastatic breast cancer or non-surgical (including inflammatory).
To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT02619162
|Hospital Universitario de Fuenlabrada|
|Fuenlabrada, Madrid, Spain, 28942|
|Hospital de La Princesa|
|Madrid, Spain, 28006|
|Madrid, Spain, 28223|
|Study Chair:||Marta Cardona||Fundacion CRIS de Investigación para Vencer el Cáncer|
|Responsible Party:||Centro Nacional de Investigaciones Oncologicas CARLOS III|
|Other Study ID Numbers:||
|First Posted:||December 2, 2015 Key Record Dates|
|Last Update Posted:||July 23, 2019|
|Last Verified:||July 2019|
breast cancer non metastatic
Neoplasms by Site
Steroid Synthesis Inhibitors
Molecular Mechanisms of Pharmacological Action
Hormones, Hormone Substitutes, and Hormone Antagonists
Physiological Effects of Drugs
Protein Kinase Inhibitors